Identification

Name
Enzalutamide
Accession Number
DB08899  (DB05094)
Type
Small Molecule
Groups
Approved
Description

Enzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.

Structure
Thumb
Synonyms
Not Available
External IDs
MDV 3100 / MDV-3100 / MDV3100
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
XtandiCapsule40 mgOralAstellas Pharma Inc2013-06-07Not applicableCanada
XtandiCapsule40 mg/1OralAstellas Pharma Inc2012-08-31Not applicableUs
XtandiCapsule40 mgOralAstellas Pharma Europe Bv2013-06-21Not applicableEu
Categories
UNII
93T0T9GKNU
CAS number
915087-33-1
Weight
Average: 464.436
Monoisotopic: 464.093009286
Chemical Formula
C21H16F4N4O2S
InChI Key
WXCXUHSOUPDCQV-UHFFFAOYSA-N
InChI
InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
IUPAC Name
4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide
SMILES
CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F

Pharmacology

Indication

Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

Associated Conditions
Pharmacodynamics

Resitance to enzalutamide therapy has been observed. This may occurred due to an upregulation of NF-κB2/p52.

Mechanism of action

Enzalutamide is a competitive androgen receptor inhibitor that effects multiple stages of the signalling pathway. It is able to inhibit androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with DNA. As a result, proliferation of prostate cancer cells decreases which ultimately leads to apoptosis and decreased tumour volume.

TargetActionsOrganism
AAndrogen receptor
inhibitor
Human
Absorption

The pharmacokinetic profile of enzalutamide and N-desmethyl enzalutamide (its major active metabolite) is described by a linear two-compartment model with first-order absorption. Enzalutamide also accumulates. Food does not affect its absorption. Tmax, prostate cancer patients = 1 hour (range of 0.5-3 hours); Cmax, steady state, enzalutamide = 16.6 μg/mL; Cmax, steady state, N-desmethyl enzalutamide = 12.7 μg/mL; Time to steady state, daily dosing = 28 days;

Volume of distribution

Apparent volume of distribution (Vd/F), single oral dose = 110 L

Protein binding

Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. N-desmethyl enzalutamide is 95% bound to plasma proteins.

Metabolism

Enzalutamide is hepatically metabolized, primarily by CYP2C8 and CYP3A4. The enzyme that converts enzalutamide to its active metabolite, N-desmethyl enzalutamide, is CYP2C8. The activity of N-desmethyl-enzalutamide is similar to that of the parent compound.

Route of elimination

Enzalutamide is primarily eliminated by hepatic metabolism. 71% of the dose is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide).

Half life

The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.

Clearance

Apparent clearance (CL/F), single oral dose = 0.56 L/h (range of 0.33 - 1.02 L/h)

Toxicity

The most common adverse reactions (≥ 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Enzalutamide.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be decreased when it is combined with Enzalutamide.Experimental, Illicit
AbemaciclibThe serum concentration of Abemaciclib can be decreased when it is combined with Enzalutamide.Approved, Investigational
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Enzalutamide.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Enzalutamide.Approved, Investigational
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Enzalutamide.Approved
Acetyl sulfisoxazoleThe metabolism of Enzalutamide can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Enzalutamide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Enzalutamide.Experimental
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Enzalutamide.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Enzalutamide.Approved
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Enzalutamide.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Enzalutamide.Experimental, Investigational
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Enzalutamide.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Enzalutamide.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Enzalutamide.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Enzalutamide.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Enzalutamide.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Enzalutamide.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
alpha-Tocopherol acetateThe serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Enzalutamide.Approved
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Enzalutamide.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Enzalutamide.Approved, Investigational
AmcinonideThe serum concentration of Amcinonide can be decreased when it is combined with Enzalutamide.Approved
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Enzalutamide.Approved
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Enzalutamide.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Enzalutamide.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Enzalutamide.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Enzalutamide.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Enzalutamide.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Enzalutamide.Approved, Investigational, Withdrawn
AndrostenedioneThe serum concentration of Androstenedione can be decreased when it is combined with Enzalutamide.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be decreased when it is combined with Enzalutamide.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be decreased when it is combined with Enzalutamide.Investigational
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Enzalutamide.Approved, Investigational
ApalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Enzalutamide.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Enzalutamide.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Enzalutamide.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Enzalutamide.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Enzalutamide resulting in a loss in efficacy.Approved
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Enzalutamide.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Enzalutamide.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
AtamestaneThe serum concentration of Atamestane can be decreased when it is combined with Enzalutamide.Investigational
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Enzalutamide.Approved, Investigational
AtomoxetineThe metabolism of Enzalutamide can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Enzalutamide.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Enzalutamide.Approved
AvatrombopagThe serum concentration of Avatrombopag can be decreased when it is combined with Enzalutamide.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Enzalutamide.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Enzalutamide.Approved
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Enzalutamide.Investigational
BaricitinibThe serum concentration of Baricitinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Enzalutamide.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Enzalutamide.Approved
BenidipineThe serum concentration of Benidipine can be decreased when it is combined with Enzalutamide.Approved, Investigational
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Enzalutamide.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Enzalutamide.Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Enzalutamide.Approved, Investigational
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Enzalutamide.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Enzalutamide.Approved, Investigational
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Enzalutamide.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Enzalutamide.Approved, Investigational
BioallethrinThe serum concentration of Bioallethrin can be decreased when it is combined with Enzalutamide.Approved, Experimental
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Enzalutamide.Approved
BlonanserinThe serum concentration of Blonanserin can be decreased when it is combined with Enzalutamide.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Enzalutamide.Approved, Investigational
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Enzalutamide.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Enzalutamide.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Enzalutamide.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
BrigatinibThe serum concentration of Brigatinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Enzalutamide.Approved
BrivaracetamThe serum concentration of Brivaracetam can be decreased when it is combined with Enzalutamide.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Enzalutamide.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Enzalutamide.Approved
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Enzalutamide.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Enzalutamide.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Enzalutamide.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Enzalutamide.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Enzalutamide.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Enzalutamide.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Enzalutamide.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Enzalutamide.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Enzalutamide.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.Approved
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Enzalutamide.Approved, Investigational
CarbamazepineThe serum concentration of Enzalutamide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Enzalutamide.Approved
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Enzalutamide.Approved, Investigational
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Enzalutamide.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Enzalutamide.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Enzalutamide.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Enzalutamide.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Enzalutamide.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Enzalutamide.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Enzalutamide.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Enzalutamide.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Enzalutamide.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Enzalutamide.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Enzalutamide.Approved, Investigational
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Enzalutamide.Approved
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Enzalutamide.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Enzalutamide.Approved
ClemastineThe metabolism of Enzalutamide can be decreased when combined with Clemastine.Approved, Investigational
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Enzalutamide.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be decreased when it is combined with Enzalutamide.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be decreased when it is combined with Enzalutamide.Approved
ClobetasoneThe serum concentration of Clobetasone can be decreased when it is combined with Enzalutamide.Approved
ClocortoloneThe serum concentration of Clocortolone can be decreased when it is combined with Enzalutamide.Approved
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Enzalutamide.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Enzalutamide.Approved, Investigational
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Enzalutamide.Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Enzalutamide.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Enzalutamide.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Enzalutamide.Approved
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Enzalutamide.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Enzalutamide.Approved, Illicit
ClotrimazoleThe metabolism of Enzalutamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Enzalutamide.Approved
CobicistatThe serum concentration of Enzalutamide can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Enzalutamide.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Enzalutamide.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Enzalutamide.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Enzalutamide.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Enzalutamide.Approved
CopanlisibThe serum concentration of Copanlisib can be decreased when it is combined with Enzalutamide.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be decreased when it is combined with Enzalutamide.Investigational
CorticosteroneThe serum concentration of Corticosterone can be decreased when it is combined with Enzalutamide.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Enzalutamide.Approved, Investigational
CrisaboroleThe metabolism of Enzalutamide can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Enzalutamide.Approved
CurcuminThe serum concentration of Enzalutamide can be increased when it is combined with Curcumin.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Enzalutamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Enzalutamide.Experimental
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Enzalutamide.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enzalutamide.Approved
DabrafenibThe serum concentration of Enzalutamide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Enzalutamide.Approved, Investigational
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Enzalutamide.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Enzalutamide.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Enzalutamide.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Enzalutamide.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Enzalutamide.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Enzalutamide.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Enzalutamide.Approved
DeferasiroxThe serum concentration of Enzalutamide can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be decreased when it is combined with Enzalutamide.Approved, Investigational
DelamanidThe serum concentration of Delamanid can be decreased when it is combined with Enzalutamide.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Enzalutamide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Enzalutamide.Approved
DesonideThe serum concentration of Desonide can be decreased when it is combined with Enzalutamide.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be decreased when it is combined with Enzalutamide.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Enzalutamide.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Enzalutamide.Experimental, Vet Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Enzalutamide.Approved, Investigational
DeutetrabenazineThe serum concentration of Deutetrabenazine can be decreased when it is combined with Enzalutamide.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Enzalutamide.Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Enzalutamide.Approved
DexlansoprazoleThe serum concentration of Dexlansoprazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Enzalutamide.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Enzalutamide.Approved
DiflorasoneThe serum concentration of Diflorasone can be decreased when it is combined with Enzalutamide.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be decreased when it is combined with Enzalutamide.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Enzalutamide.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Enzalutamide.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Enzalutamide.Approved
Dihydro-alpha-ergocryptineThe serum concentration of Dihydro-alpha-ergocryptine can be decreased when it is combined with Enzalutamide.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Enzalutamide.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Enzalutamide.Approved, Investigational
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Enzalutamide.Approved, Investigational
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Enzalutamide.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Enzalutamide.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Enzalutamide.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Enzalutamide.Approved, Investigational
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Enzalutamide.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Enzalutamide.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Enzalutamide.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Enzalutamide.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Enzalutamide.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Enzalutamide.Approved, Investigational
DoxycyclineThe metabolism of Enzalutamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Enzalutamide.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Enzalutamide.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Enzalutamide.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Enzalutamide.Approved
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Enzalutamide.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be decreased when it is combined with Enzalutamide.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Enzalutamide.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Enzalutamide.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Enzalutamide.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Enzalutamide.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Enzalutamide.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Enzalutamide.Approved
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Enzalutamide.Experimental
EquilinThe serum concentration of Equilin can be decreased when it is combined with Enzalutamide.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Enzalutamide.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Enzalutamide.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Enzalutamide.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Enzalutamide.Approved, Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Enzalutamide.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Enzalutamide.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Enzalutamide.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Enzalutamide.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Enzalutamide.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Enzalutamide.Approved, Investigational
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Enzalutamide.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enzalutamide.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Enzalutamide.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Enzalutamide.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be decreased when it is combined with Enzalutamide.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Enzalutamide.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Enzalutamide.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Enzalutamide.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Enzalutamide.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Enzalutamide.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Enzalutamide.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Enzalutamide.Approved, Investigational
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Enzalutamide.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Enzalutamide.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Enzalutamide.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Enzalutamide.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Enzalutamide.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Enzalutamide.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Enzalutamide.Approved, Investigational
FluasteroneThe serum concentration of Fluasterone can be decreased when it is combined with Enzalutamide.Investigational
FluconazoleThe metabolism of Enzalutamide can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Enzalutamide.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Enzalutamide.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Enzalutamide.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be decreased when it is combined with Enzalutamide.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Enzalutamide.Approved, Investigational
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
FluprednideneThe serum concentration of Fluprednidene can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be decreased when it is combined with Enzalutamide.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be decreased when it is combined with Enzalutamide.Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Enzalutamide.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be decreased when it is combined with Enzalutamide.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Enzalutamide.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be decreased when it is combined with Enzalutamide.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Enzalutamide.Approved
FluvoxamineThe metabolism of Enzalutamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Enzalutamide.Approved
FosaprepitantThe serum concentration of Enzalutamide can be increased when it is combined with Fosaprepitant.Approved
FosnetupitantThe serum concentration of Fosnetupitant can be decreased when it is combined with Enzalutamide.Approved
FosphenytoinThe serum concentration of Enzalutamide can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe serum concentration of Fostamatinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Enzalutamide.Approved, Investigational
Fusidic AcidThe serum concentration of Enzalutamide can be increased when it is combined with Fusidic Acid.Approved, Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Enzalutamide.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Enzalutamide.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Enzalutamide.Experimental
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Enzalutamide.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Enzalutamide.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Enzalutamide.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Enzalutamide.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Enzalutamide.Approved, Investigational
HalcinonideThe serum concentration of Halcinonide can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Enzalutamide.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Enzalutamide.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be decreased when it is combined with Enzalutamide.Investigational
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Enzalutamide.Approved
HistamineThe serum concentration of Histamine can be decreased when it is combined with Enzalutamide.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Enzalutamide.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Enzalutamide.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Enzalutamide.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Enzalutamide.Approved
IcotinibThe serum concentration of Icotinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Enzalutamide.Approved
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Enzalutamide.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Enzalutamide.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Enzalutamide.Approved
ImidafenacinThe serum concentration of Imidafenacin can be decreased when it is combined with Enzalutamide.Approved, Investigational
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Enzalutamide.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Enzalutamide.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Enzalutamide.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Enzalutamide.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Enzalutamide.Approved
IpecacThe serum concentration of Ipecac can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
IpratropiumThe serum concentration of Ipratropium bromide can be decreased when it is combined with Enzalutamide.Approved
IrbesartanThe metabolism of Enzalutamide can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Enzalutamide.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Enzalutamide resulting in a loss in efficacy.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Enzalutamide.Approved, Investigational
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Enzalutamide.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Enzalutamide.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be decreased when it is combined with Enzalutamide.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Enzalutamide.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Enzalutamide.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Enzalutamide.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Enzalutamide.Approved, Investigational
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Enzalutamide.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Enzalutamide.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Enzalutamide.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Enzalutamide.Experimental
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Enzalutamide.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Enzalutamide.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Enzalutamide.Approved, Investigational
LetermovirThe serum concentration of Enzalutamide can be increased when it is combined with Letermovir.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Enzalutamide.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Enzalutamide.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Enzalutamide.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Enzalutamide.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Enzalutamide.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Enzalutamide.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Enzalutamide.Approved
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Enzalutamide.Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Enzalutamide.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Enzalutamide.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Enzalutamide.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Enzalutamide.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Enzalutamide.Approved, Investigational
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Enzalutamide.Approved
LorpiprazoleThe serum concentration of Enzalutamide can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Enzalutamide.Approved
LoteprednolThe serum concentration of Loteprednol can be decreased when it is combined with Enzalutamide.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Enzalutamide.Approved, Investigational
LuliconazoleThe serum concentration of Enzalutamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Enzalutamide can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Enzalutamide.Approved
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Enzalutamide.Approved, Investigational
MacimorelinThe serum concentration of Macimorelin can be decreased when it is combined with Enzalutamide.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Enzalutamide.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Enzalutamide.Approved, Investigational
ME-609The serum concentration of ME-609 can be decreased when it is combined with Enzalutamide.Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
Medical CannabisThe serum concentration of Medical Cannabis can be decreased when it is combined with Enzalutamide.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Enzalutamide.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be decreased when it is combined with Enzalutamide.Approved
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Enzalutamide.Approved, Investigational
MelengestrolThe serum concentration of Melengestrol can be decreased when it is combined with Enzalutamide.Vet Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Enzalutamide.Approved
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Enzalutamide.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Enzalutamide.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Enzalutamide.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Enzalutamide.Experimental
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Enzalutamide.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Enzalutamide.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Enzalutamide.Approved, Investigational
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Enzalutamide.Approved, Investigational
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Enzalutamide.Investigational, Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Enzalutamide.Approved, Illicit
MidecamycinThe serum concentration of Midecamycin can be decreased when it is combined with Enzalutamide.Approved
MidostaurinThe serum concentration of Midostaurin can be decreased when it is combined with Enzalutamide.Approved, Investigational
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Enzalutamide.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Enzalutamide.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Enzalutamide.Approved
MitotaneThe serum concentration of Enzalutamide can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Enzalutamide.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Enzalutamide.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Enzalutamide.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Enzalutamide.Approved, Investigational
NabiloneThe metabolism of Enzalutamide can be decreased when combined with Nabilone.Approved, Investigational
NabiximolsThe serum concentration of Nabiximols can be decreased when it is combined with Enzalutamide.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Enzalutamide.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Enzalutamide.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be decreased when it is combined with Enzalutamide.Investigational
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Enzalutamide.Approved
NeratinibThe serum concentration of Neratinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Enzalutamide.Approved, Investigational
NevirapineThe serum concentration of Enzalutamide can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Enzalutamide.Approved, Investigational
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Enzalutamide.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Enzalutamide.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Enzalutamide.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Enzalutamide.Approved, Investigational
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Enzalutamide.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Enzalutamide.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Enzalutamide.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Enzalutamide.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Enzalutamide.Approved
OdanacatibThe serum concentration of Odanacatib can be decreased when it is combined with Enzalutamide.Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Enzalutamide.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Enzalutamide.Experimental, Investigational
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be decreased when it is combined with Enzalutamide.Investigational
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Enzalutamide.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Enzalutamide.Approved
OpiumThe serum concentration of Opium can be decreased when it is combined with Enzalutamide.Approved, Illicit
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Enzalutamide.Approved
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Enzalutamide.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Enzalutamide.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Enzalutamide.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Enzalutamide.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Enzalutamide.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Enzalutamide.Approved, Investigational
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Enzalutamide.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Enzalutamide.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Enzalutamide.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Enzalutamide.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Enzalutamide.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Enzalutamide.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Enzalutamide.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Enzalutamide.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Enzalutamide.Approved, Investigational
PentobarbitalThe serum concentration of Enzalutamide can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Enzalutamide.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Enzalutamide.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Enzalutamide.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be decreased when it is combined with Enzalutamide.Approved
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Enzalutamide.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Enzalutamide.Experimental
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Enzalutamide.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Enzalutamide.Withdrawn
PhenobarbitalThe serum concentration of Enzalutamide can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Enzalutamide.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Enzalutamide.Approved, Investigational
PhenytoinThe serum concentration of Enzalutamide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Enzalutamide.Approved, Investigational
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Enzalutamide.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Enzalutamide.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Enzalutamide.Approved
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Enzalutamide.Approved, Investigational
PiperaquineThe serum concentration of Piperaquine can be decreased when it is combined with Enzalutamide.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Enzalutamide.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be decreased when it is combined with Enzalutamide.Approved, Investigational
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Enzalutamide.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Enzalutamide.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Enzalutamide.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be decreased when it is combined with Enzalutamide.Investigational
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Enzalutamide.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Enzalutamide.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Enzalutamide.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
PrednicarbateThe serum concentration of Prednicarbate can be decreased when it is combined with Enzalutamide.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Enzalutamide.Approved, Experimental, Investigational
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Enzalutamide.Approved
PrimidoneThe serum concentration of Enzalutamide can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Enzalutamide.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Enzalutamide.Approved
PropiverineThe serum concentration of Propiverine can be decreased when it is combined with Enzalutamide.Approved, Investigational
PropofolThe serum concentration of Propofol can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Enzalutamide.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Enzalutamide.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Enzalutamide.Approved
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Enzalutamide.Approved, Investigational
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Enzalutamide.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Enzalutamide.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Enzalutamide.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Enzalutamide.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Enzalutamide.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Enzalutamide.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Enzalutamide.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Enzalutamide.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Enzalutamide.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Enzalutamide.Approved
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Enzalutamide.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Enzalutamide.Approved
RibociclibThe serum concentration of Ribociclib can be decreased when it is combined with Enzalutamide.Approved, Investigational
RifabutinThe serum concentration of Enzalutamide can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Enzalutamide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Enzalutamide can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Enzalutamide.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Enzalutamide.Approved
RimexoloneThe serum concentration of Rimexolone can be decreased when it is combined with Enzalutamide.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Enzalutamide.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Enzalutamide.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Enzalutamide.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Enzalutamide.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Enzalutamide.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Enzalutamide.Approved
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Enzalutamide.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Enzalutamide.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Enzalutamide.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Enzalutamide.Approved
RosiglitazoneThe metabolism of Enzalutamide can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Enzalutamide.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Enzalutamide.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Rucaparib can be decreased when it is combined with Enzalutamide.Approved, Investigational
RupatadineThe serum concentration of Rupatadine can be decreased when it is combined with Enzalutamide.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide.Approved
SafinamideThe serum concentration of Safinamide can be decreased when it is combined with Enzalutamide.Approved, Investigational
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Enzalutamide.Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Enzalutamide.Approved, Investigational
SarilumabThe therapeutic efficacy of Enzalutamide can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Enzalutamide.Approved
SecobarbitalThe serum concentration of Enzalutamide can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Enzalutamide.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Enzalutamide.Approved
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Enzalutamide.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Enzalutamide.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Enzalutamide.Approved
SiltuximabThe serum concentration of Enzalutamide can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Enzalutamide.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Enzalutamide.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Enzalutamide.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Enzalutamide.Approved, Investigational
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Enzalutamide.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Enzalutamide.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Enzalutamide.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Enzalutamide.Approved
St. John's WortThe serum concentration of Enzalutamide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Enzalutamide can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Enzalutamide.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Enzalutamide.Approved
SulfisoxazoleThe metabolism of Enzalutamide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Enzalutamide.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Enzalutamide.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Enzalutamide.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Enzalutamide.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Enzalutamide.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Enzalutamide.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Enzalutamide.Approved, Investigational
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Enzalutamide.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Enzalutamide.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Enzalutamide.Experimental
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Enzalutamide.Approved
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Enzalutamide.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Enzalutamide.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Enzalutamide.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
TeriflunomideThe metabolism of Enzalutamide can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Enzalutamide.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Enzalutamide.Approved, Investigational
Testosterone cypionateThe serum concentration of Testosterone cypionate can be decreased when it is combined with Enzalutamide.Approved
Testosterone enanthateThe serum concentration of Testosterone enanthate can be decreased when it is combined with Enzalutamide.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Testosterone undecanoate can be decreased when it is combined with Enzalutamide.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
TezacaftorThe serum concentration of Tezacaftor can be decreased when it is combined with Enzalutamide.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Enzalutamide.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Enzalutamide.Approved, Withdrawn
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Enzalutamide.Approved, Investigational
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Enzalutamide.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Enzalutamide.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Enzalutamide.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Enzalutamide.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Enzalutamide.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be decreased when it is combined with Enzalutamide.Approved, Withdrawn
TocilizumabThe serum concentration of Enzalutamide can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe serum concentration of Tocofersolan can be decreased when it is combined with Enzalutamide.Approved
TocopherolThe serum concentration of Tocopherol can be decreased when it is combined with Enzalutamide.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Enzalutamide.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Enzalutamide.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Enzalutamide.Approved
TopiroxostatThe metabolism of Enzalutamide can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Enzalutamide.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Enzalutamide.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Enzalutamide.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Enzalutamide.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Enzalutamide.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Enzalutamide.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Enzalutamide.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Enzalutamide.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Enzalutamide.Approved, Investigational
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Enzalutamide.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Enzalutamide.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Enzalutamide.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Enzalutamide.Investigational, Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Enzalutamide.Approved
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Enzalutamide.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Enzalutamide.Approved
UlobetasolThe serum concentration of Ulobetasol can be decreased when it is combined with Enzalutamide.Approved
ValbenazineThe serum concentration of Valbenazine can be decreased when it is combined with Enzalutamide.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Enzalutamide.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Enzalutamide.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Enzalutamide.Approved
VelpatasvirThe serum concentration of Velpatasvir can be decreased when it is combined with Enzalutamide.Approved, Investigational
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Enzalutamide.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Enzalutamide.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Enzalutamide.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Enzalutamide.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Enzalutamide.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Enzalutamide.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Enzalutamide.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Enzalutamide.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Enzalutamide.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Enzalutamide.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be decreased when it is combined with Enzalutamide.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Enzalutamide.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Enzalutamide.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Enzalutamide.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Enzalutamide.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Enzalutamide.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be decreased when it is combined with Enzalutamide.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Enzalutamide.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Enzalutamide.Approved, Investigational, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Enzalutamide.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Enzalutamide.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Enzalutamide.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Enzalutamide.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Enzalutamide.Approved
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Enzalutamide.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Enzalutamide.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Enzalutamide.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Enzalutamide.Approved
ZotepineThe serum concentration of Zotepine can be decreased when it is combined with Enzalutamide.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC: NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22. [PubMed:23699654]
External Links
KEGG Drug
D10218
PubChem Compound
15951529
PubChem Substance
175427141
ChemSpider
13093347
BindingDB
50425732
ChEBI
68534
ChEMBL
CHEMBL1082407
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Enzalutamide
ATC Codes
L02BB04 — Enzalutamide
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (393 KB)
MSDS
Download (89.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentClear Cell Renal Cell Carcinoma / Stage I Renal Cell Cancer1
1Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
1Active Not RecruitingTreatmentBladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer1
1Active Not RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
1Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
1Active Not RecruitingTreatmentNeoplasms / Solid Cancers1
1Active Not RecruitingTreatmentProstate Cancer2
1Active Not RecruitingTreatmentProstatic Neoplasms, Castration-Resistant1
1CompletedNot AvailableDrug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics1
1CompletedNot AvailableHealthy Volunteers / Kidney Diseases / Pharmacokinetics of MDV31001
1CompletedBasic ScienceCastration Resistant Prostate Cancer (CRPC) / Healthy Volunteers / MDV3100 / Relative Bioavailability1
1CompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics of Enzalutamide1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of MDV31001
1CompletedBasic ScienceNormal Hepatic Function / Severe Hepatic Impairment1
1CompletedBasic SciencePharmacokinetics of Caffeine / Pharmacokinetics of Dextromethorphan / Prostate Cancer1
1CompletedBasic SciencePharmacokinetics of Enzalutamide / Prostate Cancer1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Adenocarcinoma1
1CompletedTreatmentCastration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV31001
1CompletedTreatmentHormone Refractory Prostate Cancer / Prostate Cancer1
1CompletedTreatmentProstate Cancer1
1Not Yet RecruitingTreatmentMalignant Neoplasm of Breast1
1RecruitingOtherProstate Cancer1
1RecruitingTreatmentAdvanced Solid Tumors / Cancer, Breast / Prostate Cancer1
1RecruitingTreatmentCancers1
1RecruitingTreatmentCastration Resistant Prostate Cancer (CRPC) / Prostate Cancer1
1RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer / Prostatic Neoplasms1
1RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentMetastatic Hormone Refractory Prostate Cancer1
1WithdrawnTreatmentCancers1
1, 2Active Not RecruitingTreatmentMetastatic Castrate-Resistant Prostate Cancer1
1, 2CompletedTreatmentCastration Resistant Prostate Cancer (CRPC) / Prostate Cancer / Prostate Neoplasms1
1, 2RecruitingTreatmentCastration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2RecruitingTreatmentHepatocellular,Carcinoma1
1, 2RecruitingTreatmentHormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Carcinoma Metastatic in the Bone / Stage IV Prostate Cancer1
1, 2RecruitingTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1, 2RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer2
1, 2RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2SuspendedTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Progesterone Receptor Negative / Progesterone Receptor Positive / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2Active Not RecruitingBasic ScienceMetastatic Hormone Refractory Prostate Cancer1
2Active Not RecruitingOtherMetastatic Castration Resistant Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / High Risk Prostate Cancer / Prostate Cancer1
2Active Not RecruitingTreatmentAdvanced Breast Cancer / HER2 Amplified / Human Epidermal Growth Factor Receptor 2 (HER2)1
2Active Not RecruitingTreatmentAdvanced Hepatocellular Carcinoma1
2Active Not RecruitingTreatmentAdvanced, Androgen Receptor Positive Triple Negative Breast Cancer1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentCastration Resistant Prostate Cancer (CRPC) / Prostate Carcinoma Metastatic to the Bone1
2Active Not RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
2Active Not RecruitingTreatmentHormone-Refractory Prostate Cancer1
2Active Not RecruitingTreatmentIntermediate Risk Prostate Cancer1
2Active Not RecruitingTreatmentMetastatic Castration-Resistant Prostatic Cancer1
2Active Not RecruitingTreatmentNon-metastatic, Hormone naïve Prostate Cancer1
2Active Not RecruitingTreatmentPelvic Nodal / Prostatic Neoplasms1
2Active Not RecruitingTreatmentProstate Cancer11
2Active Not RecruitingTreatmentProstate Carcinoma Metastatic to the Bone1
2Active Not RecruitingTreatmentProstatic Neoplasms1
2CompletedTreatmentAndrogen Receptor Abnormal / DNA / Prostate Cancer1
2CompletedTreatmentCastration-Resistant Prostate Cancer (CRPC)1
2CompletedTreatmentCastration-Resistant Prostate Cancer (CRPC) / Prostate Cancer1
2CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
2CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
2CompletedTreatmentMetastatic Progressive Castration-resistant Prostate Cancer1
2CompletedTreatmentProstate Cancer4
2CompletedTreatmentProstatic Neoplasms1
2Not Yet RecruitingTreatmentCastration-Resistant Prostate Carcinoma / Prostate Carcinoma Metastatic in the Bone / Stage IV Prostate Cancer1
2Not Yet RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer / Prostate Neoplasms1
2Not Yet RecruitingTreatmentProstate Cancer1
2RecruitingOtherMetastatic Castrate-resistant Prostate (CRPC) Cancer1
2RecruitingSupportive CareAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2RecruitingTreatmentAdenocarcinoma of the Prostate2
2RecruitingTreatmentAdenocarcinoma, Prostate / Prostate Cancer1
2RecruitingTreatmentAdvanced Epithelial Ovarian / Fallopian Tubes / Primary Peritoneal Carcinoma / Recurrent Epithelial Ovarian1
2RecruitingTreatmentBone Metastases / Castration-Resistant Prostate Cancer (CRPC)1
2RecruitingTreatmentBone Metastases / Prostate Cancer1
2RecruitingTreatmentCancer of the Ovary1
2RecruitingTreatmentCancer of the Prostate / Prostate Cancer1
2RecruitingTreatmentCancer, Breast3
2RecruitingTreatmentCancer, Breast / Early Stage / Triple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentCastration Resistant Metastatic Prostate Cancer1
2RecruitingTreatmentCastration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma AJCC v7 / Stage IV Prostate Cancer1
2RecruitingTreatmentEndometrial Cancers1
2RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer / Metastatic Castration-Resistant Prostate Cancer (mCRPC)1
2RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer3
2RecruitingTreatmentPrimary Breast Cancer AR+ve TNBN / Primary Breast Cancer ER+ve1
2RecruitingTreatmentProstate Cancer9
2RecruitingTreatmentProstatic Neoplasms1
2RecruitingTreatmentSalivary Cancer1
2TerminatedPreventionBladder Cancers1
2WithdrawnTreatmentLocalized Prostate Cancer / Prostate Cancer1
2WithdrawnTreatmentMetastatic Castration Resistant Prostate Cancer1
2, 3RecruitingTreatmentCastration-resistant Prostate Cancer Patients With Oligometastases1
2, 3RecruitingTreatmentMetastasis / Metastatic Hormone Refractory Prostate Cancer1
2, 3RecruitingTreatmentProstate Cancer1
3Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
3Active Not RecruitingTreatmentCancer of the Prostate / Nonmetastatic Castration-Resistant Prostate Cancer / Prostate Cancer1
3Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentMetastatic Hormone Sensitive Prostate Cancer1
3Active Not RecruitingTreatmentProgressive Metastatic Prostate Cancer1
3Active Not RecruitingTreatmentProstate Cancer1
3Active Not RecruitingTreatmentProstatic Neoplasms1
3CompletedTreatmentCastration-Resistant Prostate Cancer (CRPC)1
3RecruitingTreatmentCancer of the Prostate / Hormone Sensitive Prostate Cancer / Prostate Cancer1
3RecruitingTreatmentCancer, Breast1
3RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
3RecruitingTreatmentProstate Cancer1
3RecruitingTreatmentProstatic Neoplasms1
3RecruitingTreatmentProstatic Neoplasms, Castration-Resistant1
3TerminatedTreatmentProstate Cancer1
4Active Not RecruitingTreatmentMetastatic Castration-Resistant Prostate Cancer (mCRPC)1
4Active Not RecruitingTreatmentProstate Cancer2
4CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
4RecruitingSupportive CareCastration-Resistant Prostatic Cancer / Hormone-Refractory Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
4RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
4TerminatedTreatmentMetastatic Castration Resistant Prostate Cancer1
Not AvailableActive Not RecruitingNot AvailableAdenocarcinoma, Prostate / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
Not AvailableActive Not RecruitingNot AvailableCastration-Resistant Prostate Cancer (CRPC)1
Not AvailableActive Not RecruitingNot AvailableMetastatic Castration Resistant Prostate Cancer1
Not AvailableActive Not RecruitingNot AvailableProstatic Neoplasms, Castration-Resistant1
Not AvailableActive Not RecruitingTreatmentProstate Cancer1
Not AvailableApproved for MarketingNot AvailableMetastatic Castration Resistant Prostate Cancer1
Not AvailableCompletedNot AvailableMetastatic Castration Resistant Prostate Cancer1
Not AvailableRecruitingNot AvailableProstate Cancer1
Not AvailableRecruitingTreatmentAdenocarcinoma of the Prostate / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma in the Soft Tissue / Metastatic Prostatic Adenocarcinoma / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Recurrent Prostate Cancer / Recurrent Prostate Carcinoma / Stage III Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Cancer1
Not AvailableRecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Stage IV Prostate Cancer1
Not AvailableRecruitingTreatmentAnn Arbor Stage I Mantle Cell Lymphoma / Ann Arbor Stage II Mantle Cell Lymphoma / Ann Arbor Stage III Mantle Cell Lymphoma / Ann Arbor Stage IV Mantle Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
Not AvailableRecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
Not AvailableTerminatedTreatmentProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral40 mg
CapsuleOral40 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8183274No2006-05-152026-05-15Us
US9126941No2006-05-152026-05-15Us
US7709517No2007-08-132027-08-13Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00136 mg/mLALOGPS
logP3.75ALOGPS
logP4.16ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)13.05ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area76.44 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity113.48 m3·mol-1ChemAxon
Polarizability42.71 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9356
Blood Brain Barrier+0.8514
Caco-2 permeable+0.5219
P-glycoprotein substrateNon-substrate0.7609
P-glycoprotein inhibitor IInhibitor0.6464
P-glycoprotein inhibitor IIInhibitor0.5693
Renal organic cation transporterNon-inhibitor0.899
CYP450 2C9 substrateNon-substrate0.7447
CYP450 2D6 substrateNon-substrate0.8061
CYP450 3A4 substrateSubstrate0.5589
CYP450 1A2 substrateNon-inhibitor0.5613
CYP450 2C9 inhibitorInhibitor0.7126
CYP450 2D6 inhibitorNon-inhibitor0.9148
CYP450 2C19 inhibitorInhibitor0.6882
CYP450 3A4 inhibitorInhibitor0.6184
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6711
Ames testNon AMES toxic0.683
CarcinogenicityNon-carcinogens0.7232
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4319 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9911
hERG inhibition (predictor II)Inhibitor0.7079
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0321900000-b1c610c4a717fdea030e

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylimidazolidines. These are polycyclic compounds containing an imidazoline substituted by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Imidazolidines
Direct Parent
Phenylimidazolidines
Alternative Parents
Trifluoromethylbenzenes / 2-halobenzoic acids and derivatives / Alpha amino acids and derivatives / N-phenylthioureas / Benzamides / Benzoyl derivatives / Benzonitriles / Fluorobenzenes / Aryl fluorides / Imidazolidinones
show 11 more
Substituents
Phenylimidazolidine / Alpha-amino acid or derivatives / Trifluoromethylbenzene / N-phenylthiourea / 2-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzamide / Benzoic acid or derivatives / Benzonitrile / Benzoyl
show 29 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
benzamides, nitrile, imidazolidinone, monofluorobenzenes, (trifluoromethyl)benzenes, thiocarbonyl compound (CHEBI:68534)

Targets

Details
1. Androgen receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on June 04, 2013 23:12 / Updated on June 24, 2018 20:22